Gilead cashes in $125m voucher for faster HIV combo review
This article was originally published in Scrip
Executive Summary
Gilead Sciences has decided to cash in a voucher it paid big bucks for to gain a quicker US review of its once-daily single tablet combination regimen, which consists of the firm's emtricitabine 200mg and tenofovir alafenamide (TAF) 25mg with Janssen's rilpivirine 25mg.